Sirna Therapeutics said last week that Marvin Tancer, CFO and vice president of operations, has left the company to pursue other opportunities.
In June 2001, Tancer joined Ribozyme Pharmaceuticals. The next year, he helped oversee the company’s $48 million private stock placement and transformation into RNAi therapeutics firm Sirna.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
